سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Rahmani, Behnaz, Astani, Akram, Zarei Jaliani, Hossein, Kheirandish, Mohammad Hassan, Mosadegh, Ahmad. (1400). Evaluation of kinetic stability and anti-staphylococcal activity of recombinant LasA protein produced in Escherichia coli. , 24(6), 851-855. doi: 10.22038/ijbms.2021.54563.12250
Behnaz Rahmani; Akram Astani; Hossein Zarei Jaliani; Mohammad Hassan Kheirandish; Ahmad Mosadegh. "Evaluation of kinetic stability and anti-staphylococcal activity of recombinant LasA protein produced in Escherichia coli". , 24, 6, 1400, 851-855. doi: 10.22038/ijbms.2021.54563.12250
Rahmani, Behnaz, Astani, Akram, Zarei Jaliani, Hossein, Kheirandish, Mohammad Hassan, Mosadegh, Ahmad. (1400). 'Evaluation of kinetic stability and anti-staphylococcal activity of recombinant LasA protein produced in Escherichia coli', , 24(6), pp. 851-855. doi: 10.22038/ijbms.2021.54563.12250
Rahmani, Behnaz, Astani, Akram, Zarei Jaliani, Hossein, Kheirandish, Mohammad Hassan, Mosadegh, Ahmad. Evaluation of kinetic stability and anti-staphylococcal activity of recombinant LasA protein produced in Escherichia coli. , 1400; 24(6): 851-855. doi: 10.22038/ijbms.2021.54563.12250

Evaluation of kinetic stability and anti-staphylococcal activity of recombinant LasA protein produced in Escherichia coli

Iranian Journal of Basic Medical Sciences
مقاله 17، دوره 24، شماره 6، شهریور 2021، صفحه 851-855    اصل مقاله (558.7 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2021.54563.12250
نویسندگان
Behnaz Rahmani1، 2؛ Akram Astani1، 3؛ Hossein Zarei Jaliani* 2؛ Mohammad Hassan Kheirandish2؛ Ahmad Mosadegh1
1Department of Microbiology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3Zoonotic Diseases Research Center, Department of Food Hygiene and Safety, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
چکیده
Objective(s): Staphylococcus aureus has become a major clinical concern due to the growing prevalence of multi-drug resistant (MDR) strains. Enzybioticts are peptidoglycan hydrolases that are recently introduced as an alternative agent to confront the MDR strains with a more effective mechanism than conventional antibiotics.  In this regard, our study aimed to evaluate the kinetic stability of LasA protease as a potent enzybiotic in the specific destruction of the S. aureus cell wall.
Materials and Methods: The catalytic domain of the Codon-optimized LasA gene was sub-cloned into pET28a vector, and BL21 DE3 cells were used for protein expression. Recombinant LasA protein was affinity purified by Ni-NTA column and staphylolytic activity of the LasA protein against methicillin-resistant strains was evaluated by disk diffusion and MIC test. The kinetic stability was evaluated in different temperatures during 48 hr.
Results: Our results revealed that LasA protein can completely prevent the growth of Methicillin-resistant S. aureus (MRSA) strain and inhibit the examined strain at the amount of 4 µg. furthermore, the catalytic domain of LasA protein can tolerate higher temperatures as well.
Conclusion: With regard to the failure of conventional antibiotics in treatment of MRSA infections, novel agents to combat multidrug-resistant strains are needed. The present study shows that LasA protein can eradicate MRSA strains, so it can be promising for the treatment of antibiotic-resistant staphylococci infection. The kinetic stability of LasA has also confirmed the possibility of industrial-scale manufacturing for the subsequent use of the enzyme clinically.
کلیدواژه‌ها
Antibiotic؛ LasA protease؛ MRSA؛ Stability؛ Staphylolysin
مراجع
1. Rao Q, Shang W, Hu X, Rao X. Staphylococcus aureus ST121: a globally disseminated hypervirulent clone. J Med Microbiol 2015; 64:1462-1473.
2. Haaber J, Penadés JR, Ingmer H. Transfer of antibiotic resistance in Staphylococcus aureus. Trends Microbiol 2017; 25:893-905.
3. Alibayov B, Baba-Moussa L, Sina H, Zdeňková K, Demnerová K. Staphylococcus aureus mobile genetic elements. Mol Biol Rep 2014; 41:5005-5018.
4. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: a guide for clinicians. J Anaesthesiol Clin Pharmacol 2017; 33:300-305.
5. Elward AM, McAndrews JM, Young VL. Methicillin-sensitive and methicillin-resistant Staphylococcus aureus: preventing surgical site infections following plastic surgery. Aesthet Surg J 2009; 29:232-244.
6. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:S165-S170.
7. Hojckova K, Stano M, Klucar L. phiBIOTICS: catalogue of therapeutic enzybiotics, relevant research studies and practical applications. BMC Microbiol 2013; 13:53.
8. Bebell LM, Muiru AN. Antibiotic use and emerging resistance: How can resource-limited countries turn the tide? Glob Heart 2014; 9:347-358.
9. Pai A, Sudhakar G, Kamath V. Enzybiotics-A review. Int J Pharm Res 2013; 3:69-71.
10. Wu H, Lu H, Huang J, Li G, Huang Q. EnzyBase: A novel database for enzybiotic studies. BMC Microbiol 2012; 12:54.
11. Veiga-Crespo P, Sanchez-Perez A, Villa TG. Enzybiotics: The rush toward prevention and control of multiresistant bacteria (MRB). Antimicrobial Compounds: Springer; 2014. p. 215-235.
12. Kessler E, Safrin M, Gustin JK, Ohman DE. Elastase and the LasA protease of Pseudomonas aeruginosa are secreted with their propeptides. J Biol Chem 1998; 273:30225-30231.
13. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48:5-16.
14. Jaśkiewicz M, Neubauer D, Kazor K, Bartoszewska S, Kamysz W. Antimicrobial activity of selected antimicrobial peptides against planktonic culture and biofilm of Acinetobacter baumannii. Probiotics Antimicrob Proteins 2019; 11:317-324.
15. Sanchez-Ruiz JM. Protein kinetic stability. Biophys Chem 2010; 148:1-15.
16. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015; 40:277-283.
17. Goldberg JB, Ohman DE. Activation of an elastase precursor by the lasA gene product of Pseudomonas aeruginosa J Bacteriol 1987; 169:4532-4539.
18. Schad PA, Iglewski BH. Nucleotide sequence and expression in Escherichia coli of the Pseudomonas aeruginosa lasA gene. J Bacteriol 1988; 170:2784-2789.
19. Szweda P, Schielmann M, Kotlowski R, Gorczyca G, Zalewska M, Milewski S. Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus. Appl Microbiol Biotechnol 2012; 96:1157-1174.
20. Kessler E, Safrin M, Abrams WR, Rosenbloom J, Ohman DE. Inhibitors and specificity of Pseudomonas aeruginosa LasA. J Biol Chem 1997; 272:9884-9889.
21. Barequet IS, Ben Simon GJ, Safrin M, Ohman DE, Kessler E. Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis. Antimicrob Agents Chemother 2004; 48:1681-1687.
22. Barequet IS, Habot-Wilner Z, Mann O, Safrin M, Ohman DE, Kessler E, et al. Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model. Graefes Arch Clin Exp Ophthalmol 2009; 247:913-917.
23. Peters JE, Galloway DR. Purification and characterization of an active fragment of the LasA protein from Pseudomonas aeruginosa: Enhancement of elastase activity. J Bacteriol 1990; 172:2236-2240.

آمار
تعداد مشاهده مقاله: 608
تعداد دریافت فایل اصل مقاله: 440